Skip to main content

Simple Western Hits the Bullseye of Targeted Protein Degradation

by Charles Haitjema, Ph.D. Bio-Techne

Scientific Articles

Scientific Articles Summary

Simple Western Hits the Bullseye of Targeted Protein Degradation

Western Blot Misses the Mark

Finding the right degrader is like finding a needle in a haystack. Researchers in targeted protein degradation (TPD) need speed, precision, and throughput to find the sweet spot of degrader efficiency, screening many samples of varying concentrations and time points. Researchers generally run dose-response curves using traditional SDS-PAGE Western blotting methods to characterize the efficacy of degradation molecules. However, the lengthy, manual workflow and resulting low reproducibility make Western blot unreliable for TPD measurements like DC50 values.

Instead, the ideal solution would be highly reproducible, allow for easy quantitation, and have a short time for results. Simple Western™ is just that, letting you separate and analyze proteins by size from 2 kDa to 440 kDa in just 3 hours. With the push of a button, researchers can process up to 96 samples in a hands-free Simple Western run, with quantitative results and reproducibility for accurate dose-response measurements. Plus, Simple Western is an open platform, and conventional Western blot antibodies may be used for detection, eliminating the need for epitope tags that can interfere with degrader activity. Choose from thousands of Simple Western validated antibodies or validate your own antibody.

Simple Western in the Hands of Your Peers

Leading TPD researchers across the globe are turning to Simple Western to monitor protein degradation activity and advance cutting-edge targeted protein degradation research, supported by the steady increase in publications in premier journals like Cell, Nature Chemical Biology, and PNAS.

This review highlights vital publications that represent Simple Western’s high-throughput screening of degrader activity with reproducible quantification, flexible multiplex strategies, and fast time to results, from drug discovery of novel degraders through translation to the clinic.

Request Literature

To access this literature content please fill out the form below.